Bio-Rad Laboratories (Bio-Rad Laboratories) Total Liabilities : $3,558 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Bio-Rad Laboratories Total Liabilities?

Bio-Rad Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 was $3,558 Mil.

Bio-Rad Laboratories's quarterly Total Liabilities declined from Jun. 2023 ($3,531.34 Mil) to Sep. 2023 ($3,479.75 Mil) but then increased from Sep. 2023 ($3,479.75 Mil) to Dec. 2023 ($3,557.94 Mil).

Bio-Rad Laboratories's annual Total Liabilities declined from Dec. 2021 ($4,114.16 Mil) to Dec. 2022 ($3,886.41 Mil) and declined from Dec. 2022 ($3,886.41 Mil) to Dec. 2023 ($3,557.94 Mil).

Bio-Rad Laboratories Total Liabilities Historical Data

The historical data trend for Bio-Rad Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Total Liabilities Chart

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,253.80

3,092.68

4,114.16

3,886.41

3,557.94

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															3,886.41	3,903.70	3,531.34	3,479.75	3,557.94

Bio-Rad Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bio-Rad Laboratories's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	522.799	+	(1364.578	+	195.065
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1475.495	+	0)
	=	3,558

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	12299.07	-	8741.133
	=	3,558

Bio-Rad Laboratories's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	522.799	+	(1364.578	+	195.065
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1475.495	+	0)
	=	3,558

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	12299.07	-	8741.133
	=	3,558

Bio-Rad Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BIO:USA BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.